Autres langues

26/03 Orgenesis : Annual Report for Fiscal Year Ending December 31, 2024 (Form 10-K)
26/03 Orgenesis Inc. Reports Earnings Results for the Full Year Ended December 31, 2024
26/03 Orgenesis Inc. Auditor Raises 'Going Concern' Doubt
26/03 Okogen, Inc. acquired Global intellectual property portfolio and development assets for ranpirnase from Orgenesis Inc..
13/03 Orgenesis Inc. Announces Board Appointments, Effective March 10, 2026
13/03 Orgenesis Inc. Appoints Doug Karriker as Chief Financial Officer, Effective March 10, 2026
25/08/25 Orgenesis Inc. Announces Resignation of Director Ashish Nanda, Effective August 21, 2025
19/08/25 Orgenesis Inc. Announces Resignation of Victor Miller as Chief Financial Officer
19/08/25 Orgenesis Inc. Announces Executive and Board Changes
06/03/25 Orgenesis Inc. completed the acquisition of Certain assets of Neurocords LLC for $5.7 million.
22/01/25 Orgenesis Inc. announced that it expects to receive $5 million in funding
27/12/24 Orgenesis Inc. Announces Resignation of Jagannathan Bhalaji as A Director
13/11/24 Orgenesis Provides Third Quarter 2024 Business Update
13/11/24 Tranche Update on Orgenesis Inc.'s Equity Buyback Plan announced on May 15, 2020.
13/11/24 Orgenesis Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
01/11/24 Orgenesis Inc. Announces Board Appointments
23/10/24 Orgenesis Inc. Announces Resignation of Mark Goodman as Director
23/10/24 Orgenesis Inc.(NasdaqCM:ORGS) dropped from S&P TMI Index
21/10/24 Orgenesis Commences Trading on OTCQX® Best Market
18/10/24 Top Midday Decliners
18/10/24 Wall Street Set to Open Mixed Friday as Investors Look to End Week on High Note
18/10/24 Markets Look to Close Out Strong Week as US Futures Mixed in Friday's Premarket
18/10/24 Orgenesis Shares Fall Pre-Bell Amid Nasdaq Panel Deciding to Delist Shares
18/10/24 Top Premarket Decliners
18/10/24 Orgenesis Inc.(OTCPK:ORGS) dropped from NASDAQ Composite Index
Aucun résultat pour cette recherche